Details
The purpose of this activity was to develop a White Paper that addresses the suitability of using Sentinel to estimate vaccine effectiveness. The three aims were:
- Provide an overview of study designs and methods used to estimate vaccine effectiveness in claims and electronic health data.
- Address the strengths and limitations of using Sentinel data and infrastructure to estimate vaccine effectiveness.
- If estimating vaccine effectiveness in Sentinel is feasible, the most suitable study design will be selected to implement Sentinel and potential use cases will be provided.
Additional Information
Contributors
Meghan Baker, MD, ScD; Catherine Panozzo, MPH, PhD; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA
Maria Said, MD, MHS; Azadeh Shoaibi, MS, MHS; Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD
Roger Baxter; Bruce Fireman, MD; Nicola Klein, MD, PhD; Kaiser Permanente Northern California, Vaccine Study Center, Oakland, CA
Elizabeth Dee, MPH; Sandra Feibelmann, MPH; Hana Lipowicz, MPH; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA
Kevin Fahey; America’s Health Insurance Plans, Inc., Washington, DC, Department of Population Medicine
Lisa Jackson, MD, MPH; Kaiser Washington Health Research Institute, Seattle, WA
James D. Nordin, MD, MPH; HealthPartners Institute for Education and Research, Minneapolis, MN
Deepa Arya, MD, MPH, MBA; Richard A. Forshee, PhD; Hector S. Izurieta, MD, MPH; Yun Lu, PhD; David Menschik, MD, MPH; Douglas Pratt, MD, MPH; Jane Woo, MD; Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD
Carla V. Rodriguez, PhD, MPH; Mid-Atlantic Kaiser Permanente Research Institute, Rockville, MD
Nandini Selvam, PhD, MPH, HealthCore Inc, Alexandria, VA